SMPD1 and schizophrenia: The aforementioned studies of RBCs, epidermis, and brain tissues have identified abnormalities of specific lipid species of sphingomyelin and ceramide and their associations with symptoms and cognitive performance of patients with schizophrenia, and suggest that ASM, ceramide, sphingomyelin, and S1P may represent therapeutic targets.